Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?
作者信息
Ingle James N
出版信息
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S15. doi: 10.1186/bcr2175. Epub 2008 Dec 18.
Abstract
摘要
相似文献
1
Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S15. doi: 10.1186/bcr2175. Epub 2008 Dec 18.
2
Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
Crit Rev Oncol Hematol. 2012 Nov;84(2):243-51. doi: 10.1016/j.critrevonc.2012.03.004. Epub 2012 Apr 10.
3
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Expert Rev Anticancer Ther. 2009 Feb;9(2):187-98. doi: 10.1586/14737140.9.2.187.
4
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Breast Cancer Res. 2005;7(5):205-11. doi: 10.1186/bcr1287. Epub 2005 Jul 20.
5
Endocrine resistance in breast cancer: what really matters?
Ann Oncol. 2007 Aug;18(8):1289-91. doi: 10.1093/annonc/mdm359.
6
Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?
Future Oncol. 2017 Jul;13(16):1361-1364. doi: 10.2217/fon-2017-0101. Epub 2017 Jul 7.
7
Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
Breast Cancer Res Treat. 2005;93 Suppl 1:S1-2. doi: 10.1007/s10549-005-9035-5.
8
Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models.
Breast Cancer Res. 2005;7(5):187-9. doi: 10.1186/bcr1289. Epub 2005 Jul 18.
9
Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer.
Epigenomics. 2013 Dec;5(6):595-8. doi: 10.2217/epi.13.70.
10
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clin Cancer Res. 2003 Jan;9(1 Pt 2):443S-6S.
本文引用的文献
1
Integration of endocrine therapy with targeted agents.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S20. doi: 10.1186/bcr2180. Epub 2008 Dec 18.
2
Identification and mechanisms of endocrine resistance.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2179. Epub 2008 Dec 18.
3
Markers of endocrine sensitivity.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S18. doi: 10.1186/bcr2178. Epub 2008 Dec 18.
4
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S17. doi: 10.1186/bcr2177. Epub 2008 Dec 18.
5
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S16. doi: 10.1186/bcr2176. Epub 2008 Dec 18.
Zotero 插件